Breast Neoplasms  >>  pegylated liposomal doxorubicin  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegylated liposomal doxorubicin / Generic mfg.
NCT00082095: To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

Terminated
3
62
US
Pegylated liposomal doxorubicin, DOXIL, Capecitabine, Xeloda
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Metastatic Breast Cancer
12/05
12/05
NCT00245050: Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

Completed
3
34
US
pyridoxine hydrochloride, Placebo, doxorubicin HCL liposome
Case Comprehensive Cancer Center, National Cancer Institute (NCI)
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
04/08
09/11
NCT00091442: A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

Completed
3
751
US, Europe, RoW
Docetaxel, DOXIL, DOXIL in combination with Docataxel
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Breast Cancer
12/08
12/08
P04445, NCT00266799: The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (/MK-2746-071)

Completed
3
210
NA
Pegylated liposomal doxorubicin (SCH 200746), Capecitabine
Merck Sharp & Dohme LLC, Essex Pharma GmbH
Breast Cancer
09/10
10/10

Download Options